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Hypertension affects approximately 20 to 30% of individuals in industri-
alized countries, and is commonly believed to develop on the basis of both
genetic and environmental factors. The identification of genes susceptibile
to the most frequent form of hypertension, commonly referred to as
“essential” hypertension, is hampered by the fact that blood pressure is a
poorly defined phenotype that is modulated by multiple factors, such as
gender, race, body mass etc., and that the definition of hypertension
depends on a rather arbitrarily chosen cut-off value. Hence, more progress
has been made in the identification of genes responsible for rare autoso-
mal dominant forms of hypertension, such as Liddle’s disease. This review
focuses on an experimental approach that attempts to define candidate
genes for essential hypertension using immortalized cells from well
characterized normotensive and hypertensive subjects. From the presently
available results, one attractive speculation is that an increased intracel-
lular signal transduction caused by an enhanced reactivity of Gi-type G
proteins represents a genetically fixed trait that renders affected individ-
uals susceptible to essential hypertension.
It is generally agreed that essential hypertension is a multifac-
torial polygenetic disorder [1, 2]. Current research efforts aim at
identifying those genes that increase the susceptibility for hyper-
tension either alone or in combination with other genes and/or
environmental factors.
Several quite different experimental strategies exist to identify
such “hypertension genes.” One involves the examination of rare
autosomal dominant forms of hypertension, such as Liddle’s
disease, which is caused by mutations in the b or g subunits of the
epithelial sodium channel [3, 4]. Schuster et al focused their
investigations on a Turkish family with severe autosomal domi-
nant hypertension that cosegregates 100% with brachydactyly and
maps to chromosome 12p [5]. Interestingly, this form of hyper-
tension, despite very early onset and steep increase in blood
pressure, resembles the common form of essential hypertension
[6], and identification of the responsible gene(s) in that Turkish
kindred therefore can be expected to be of major importance for
understanding the genetic basis of essential hypertension. Other
strategies rely predominantly on genetic linkage analysis, which
has led to the identification of a common M235T variant in the
gene encoding for angiotensinogen [7].
Animal models of hypertension are very useful for the identi-
fication of hypertension genes, as illustrated by the recent findings
of Cusi et al [8]. These authors could identify a polymorphism in
the a-adducin gene that is tightly associated with salt sensitivity in
patients with essential hypertension. Originally, this protein was
identified as a possible candidate gene in the Milan hypertensive
strain of rats, and mutations within the adducin genes were shown
to be associated with blood pressure variations in these animals
[9].
Finally, one method that remains very useful in defining genes
susceptible to hypertension consists of the “classical” candidate
gene approach. This method depends on the careful characteriza-
tion of intermediate phenotypes in essential hypertension, that is,
traits that are obviously inherited and tightly linked to, but not
necessarily directly involved in the pathogenesis of essential
hypertension.
This review will focus on our attempts to identify novel hyper-
tension candidate genes.
NA1/H1 EXCHANGER ACTIVITY AS AN INTERMEDIATE
PHENOTYPE IN ESSENTIAL HYPERTENSION
The Na1/H1 exchanger isoform-1 (NHE-1) is a ubiquitously
expressed ion transport protein that mediates electroneutral
exchange of extracellular Na1 ions against intracellular protons,
thereby contributing to intracellular pH homeostasis. Most likely
this protein also mediates Na1/Li1 countertransport [10, 11],
which constitutes an established genetic marker for hypertension
[12, 13]. Multiple studies have shown that the activity of the
Na1/H1 exchanger isoform-1 (NHE-1) is enhanced in a group of
patients with essential hypertension, and this enhancement of
NHE activity was found in all cells and tissues investigated, such
as erythrocytes, platelets, lymphocytes, and even skeletal muscle
in vivo [reviewed in 14–16]. However, the activity of the NHE-1 is
known to be increased in vitro by phosphorylation and Ca21-
calmodulin-mediated reactions upon cell activation via G protein-
coupled receptors and receptors with tyrosine kinase activity [17,
18]. Furthermore, NHE-1 activity in vivo is enhanced by multiple
influences, such as metabolic acidosis [19, 20], oral glucose uptake
[21], acute saline infusion [22, 23], and chronic NaCl loading [24],
to name but a few. Thus, it has been impossible to draw definitive
conclusions regarding the ultimate cause of enhanced NHE-1
activity in essential hypertension, and it is conceivable that this
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phenomenon is just another reflection of an altered neuro-
humoral milieu in essential hypertension. Therefore, we decided
to approach the question of whether or not enhanced NHE-1
activity is a genetically fixed abnormality in essential hypertension
by using a novel experimental approach. We immortalized lym-
phocytes from normotensive and hypertensive subjects with low
and high NHE-1 activity in platelets and lymphocytes, respec-
tively, using Epstein Barr virus (EBV). This resulted in the
establishment of permanently growing B lymphoblast cultures,
which could then be treated identically under standard cell culture
conditions and yet never be in contact with the hypertensive in
vivo milieu. We then demonstrated that the original cellular
phenotypes of low and high NHE-1 activity were preserved in
these immortalized cell lines [25], a finding that was confirmed in
an independent study [26]. This enhanced NHE-1 activity was
strongly associated with an enhanced proliferation of these re-
spective cell lines [25] and a faster passage through the cell cycle
[27]. Subsequent studies have been aimed at identifying the
molecular mechanisms underlying this ion transport abnormality.
A mutation in the NHE-1 gene could not be detected upon direct
sequencing of the encoding cDNA [25], and an overexpression of
the NHE-1 both on the mRNA as well as the protein level could
be ruled out [25, 26]. However, the phosphorylation state of both
the NHE-1 protein and the mitogen-activated protein kinase
(MAP kinase) was significantly increased in these “hypertensive”
cell lines [28], which pointed to a more “general” abnormality in
intracellular signal transduction in these cell lines that was
presumably located upstream of MAP kinase and NHE-1 control.
We therefore focused subsequent experiments on the character-
ization of intracellular signal transduction in these immortalized
lymphoblasts from normotensive and hypertensive subjects.
ENHANCED ACTIVATION OF G PROTEINS IN
“HYPERTENSIVE” B LYMPHOBLAST CELL LINES
Upon stimulation of B lymphoblasts with platelet-activating
factor (PAF), there were distinct increases in intracellular Ca21 in
cells from hypertensive subjects with high NHE-1 activity com-
pared to cells from normotensive controls with normal NHE-1
activity [29]. These enhanced Ca21 signals resulted from an
enhanced PAF-evoked formation of inositol-1,4,5-trisphosphate,
that is, the second messenger that releases Ca21 from intracellular
stores. Furthermore, PAF-stimulated proliferation of “hyperten-
sive” lymphoblasts was significantly enhanced, although the PAF
receptor expression was not significantly different between cell
lines established from normotensive and hypertensive subjects
[29]. Previous studies had shown that the PAF receptor of
EBV-immortalized B lymphoblasts couples to pertussis toxin
(PTX)-sensitive as well as to PTX-insensitive G proteins [30].
Upon preincubation of “normotensive” and “hypertensive” cell
lines with PTX there was a strong, albeit not complete, inhibition
of PAF-evoked Ca21 signals, suggesting the involvement of both
Gi as well as Gq/11 type G proteins. Most remarkable, however,
was the finding that the observed large difference between
normotensive and hypertensive cell lines in terms of Ca21 signals
was completely blunted upon treatment with PTX. This strongly
suggested that signal transduction via PTX-sensitive G proteins
was selectively enhanced in “hypertensive” cell lines. By quanti-
fication of PAF-stimulated [35S]GTPgS binding to permeabilized
B lymphoblasts we could actually demonstrate an enhanced
activation of PTX-sensitive Gi-type G proteins in “hypertensive”
B lymphoblasts [30]. This observation was strengthened in exper-
iments in which the peptide mastoparan-7 was applied, the latter
inducing a direct, receptor-independent activation of PTX-sensi-
tive G proteins [31]. Mastoparan-7-stimulated Gi-protein activa-
tion was, on the average, enhanced twofold in lymphoblasts from
hypertensive individuals [30].
Since these above findings were obtained in cell lines estab-
lished from highly selected normotensive and hypertensive indi-
viduals, the question arose of whether enhanced G protein
activation is a rare phenomenon that may contribute to the
pathogenesis of essential hypertension in few patients only, or
whether this abnormality can be frequently observed in essential
hypertension. We therefore immortalized lymphocytes from inde-
pendently selected hypertensive and normotensive individuals
who had not been characterized previously in terms of NHE-1
activity. Larger PAF-evoked Ca21 signals mediated by Gi proteins
were more frequent in cells from hypertensive individuals com-
pared to normotensive controls, and were independent of donor
age, gender, or antihypertensive treatment (Fig. 1). From these
studies we concluded that enhanced G protein activation could
constitute a pathogenetically important mechanism in 27 to 43%
of individuals with essential hypertension [32].
STUDIES ON SKIN FIBROBLASTS
The model of immortalized lymphoblasts allows alterations in
signal transduction pathways that are ubiquitously expressed to be
studied, such as receptor-G protein coupling, and the rapid
growth of such cell lines provides a rich source of material for
biochemical studies. Nevertheless, this model also has some
inherent limitations. Although enhanced G protein activation in
“hypertensive” cell lines was consistently found in repeated
experiments conducted during a period of two years, we could not
definitively rule out that this abnormality could potentially arise
from an experimental artifact. It was still possible that the
immortalization process induced by the EBV genome was differ-
ent in cells from hypertensive and normotensive individuals and
could, finally, result in the establishment of different cellular
Fig. 1. Platelet activating factor-evoked Ca21 signals in B lymphoblasts.
Lymphocytes from normotensive (NT) and hypertensive (HT) subjects
were immortalized with Epstein Barr virus. Pertussis toxin-sensitive Ca21
signals were determined in fura-2-loaded cells upon stimulation with 100
nmol/liter platelet activating factor. Data are mean 6 SD; *P , 0.05
(modified from [32]).
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phenotypes. Furthermore, B lymphoblasts lack receptors that are
important for blood pressure regulation or control of proliferation
in the cardiovascular system. These limitations led us to establish
cultures of primary skin fibroblasts from these previously charac-
terized individuals. We hypothesized that fibroblasts from hyper-
tensive individuals would display an increased DNA synthesis,
enhanced Ca21 signals and inositol phosphate formation upon the
stimulation of receptors that predominantly couple to PTX-
sensitive G proteins. In fact, skin fibroblasts from hypertensive
individuals displayed an enhanced PTX-sensitive incorporation of
[3H]thymidine upon stimulation with lyso-phosphatidic acid
(LPA), platelet-derived growth factor (PDGF) or serum [33].
PTX-sensitive Ca21 signals were increased upon stimulation of
“hypertensive” cells with LPA, thrombin, PDGF, and sphin-
gosine-1-phosphate (SPP), whereas PTX-insensitive Ca21 signals
evoked by angiotensin II, endothelin 1, and bradykinin were not
significantly different in skin fibroblasts from normotensive and
hypertensive subjects [33]. Thus, these studies not only confirmed
the hypothesis of a selectively enhanced cellular signaling by Gi
proteins in a group of patients with essential hypertension, but
also suggested that this abnormality is simultaneously expressed in
different cell types. It should be emphasized that signal transduc-
tion pathways mediated by Gi-type G proteins are ubiquitously
expressed, especially in cells of the cardiovascular system, such as
vascular smooth muscle cells, endothelial cells, and cardiomyo-
cytes. Therefore, it is tempting to speculate that enhanced Gi
protein activation will result in increased cellular responses,
provided that receptors are activated which combine with these
respective G protein subunits (Fig. 2).
POTENTIAL REASONS FOR ENHANCED GI PROTEIN
SIGNALING IN HYPERTENSION
The simplest cause for an increased G protein activation is an
overexpression of G protein a subunits. However, lymphoblasts
from hypertensive subjects did not display an increased amount of
PTX-substrate and GTPgS binding capacity, and affinity was
similar in lymphoblasts from normotensive and hypertensive
subjects [29], which argued against an overexpression of Ga
subunits in essential hypertension. Western blot analysis of Ga
expression in skin fibroblasts yielded a similar expression pattern
of Gai2 and Gai3 in cells from hypertensive and normotensive
individuals, GaO and Gai1 being obviously absent [33]. Similarly,
we found no differences in the expression of the b subunits Gb2
or Gb4 [33]. At present, there is no evidence that enhanced Gi
protein signaling in essential hypertension is caused by an over-
expression of components of PTX-sensitive G proteins. Similar
conclusions have been drawn from earlier studies on human
platelet plasma membranes [34].
At present we favor the hypothesis that mutations in G protein
subunits may be responsible for the observed phenotype and, as
cDNA and/or genomic sequences are available for most human a,
b or g subunits, we are currently screening “candidate” G protein
subunits for the presence of mutations. Thus far, mutations in the
cDNAs encoding for the subunits Gai2, Gai3, Gb1, and Gb2 could
be excluded [33]. We speculate that functionally significant
changes will most likely be detected in bg subunits, since bg
subunits drastically enhance receptor-mediated G protein activa-
tion [35, 36], and especially reduce the requirement of activated
receptor for a subunit activation. Other groups are currently
trying to identify the gene loci responsible for enhanced Ca21
responses by linkage analysis using immortalized B lymphoblasts
from established pedigrees. Preliminary analysis suggests that
there is a significant linkage in one family to chromosome 16 [37].
CONCLUSIONS AND PERSPECTIVES
Although the ultimate reasons for enhanced G protein signaling
in patients with essential hypertension remain to be defined, the
observations in this article fit well with those of others. Increased
intracellular signal transduction was frequently observed in plate-
lets from patients with essential hypertension and, for example,
Fig. 2. Signal transduction pathways activated
upon stimulation of Gi proteins. A variety of
hormones including norepinephrine (via a2-
adrenergic receptors), angiotensin II, and
thrombin activate receptors coupled to Gi
proteins. Activated a and bg subunits influence
a variety of intracellular second messenger
systems including ion channels, adenylyl cyclase,
and the ras-raf-MAP-kinase (MAPK) pathway.
Furthermore, bg subunits can directly activate
isoforms of phospholipase Cb (PLC), thereby
inducing activation of protein kinase C (PKC)
and an elevation of the intracellular Ca21
concentration. Enhanced activation of G
proteins is predicted to cause a pronounced
activation of these pathways, which may
ultimately result in increased cell proliferation.
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increased Ca21 signals and enhanced activation of protein kinase
C were frequently reported [38, 39]. Interestingly, such differences
were not observed when platelets were stimulated with vasopres-
sin [40], which primarily activates PTX-insensitive G proteins in
platelets. The “G protein hypotheses of essential hypertension” is
also in complete agreement with the commonly held notion
suggesting that high blood pressure results from an interaction
between inherited and environmental factors. An attractive spec-
ulation is that enhanced Gi protein reactivity alone is insufficient
to result in essential hypertension in the absence of excessive
stimulation of the affected signal transduction pathways. How-
ever, environmental factors such as emotional stress could dras-
tically increase hormonal output, thereby contributing signifi-
cantly to the development of high blood pressure on the genetic
background of abnormal signal transduction.
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APPENDIX
Abbreviations used in this article are: EBV, Epstein Barr virus; G
protein, guanine nucleotide-binding protein; LPA, lysophosphatidic acid;
NHE-1, sodium-proton exchanger isoform-1; PTX, pertussis toxin; SPP,
sphingosine-1-phosphate.
NOTE ADDED IN PROOF
While this manuscript was under review, the molecular basis of en-
hanced G protein activation in hypertension was identified. A C825T
polymorphism in the gene encoding for the G protein subunit Gb3 was
shown to be associated with alternative splicing of the gene, enhanced
intracellular signal transduction, and hypertension. See SIFFERT W, ROSS-
KOPF D, SIFFERT G, BUSCH S, MORITZ A, ERBEL R, SHARMA AM, RITZ E,
WICHMANN HE, JAKOBS KH, HORSTHEMKE B: Association of a human
G-protein beta 3 subunit variant with hypertension. Nat Genet 18:45–48,
1998
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